新型抗心绞痛药伊伐布雷定

Ivabradine:a new anti-angina drug

伊伐布雷定(ivabradine)为首个选择性特异性心脏起搏电流(If)抑制剂,具有特殊的降低心率作用。临床研究表明,其在治疗稳定性心绞痛方面具有良好的疗效和安全性。现对其作用机制、药动学、临床研究、药物相互作用及不良反应等做一综述。

Ivabradine is an agent with hate rate-lowering activity in the treatment of angina. It is the first selective and specific If channal inhibitor. The clinical research shows that ivabradine has beneficial curative effect and safety on stable angina. In this paper, we reviewed the mechanism, pharmacokinetics, clinical study, drug interactions and safety of ivabradine.